Objective To investigate the current status of nonalcoholic fatty liver disease( NAFLD) in an enterprise in Xi'an,China,and to provide a scientific basis for further studies on NAFLD in Shanxi. Methods A total of 415 employees who underwent health examination in The First Affiliated Hospital of Xi'an Medical University from June to July,2014 were enrolled. All the patients underwent physical examination,abdominal ultrasound,and serological examination,and completed related questionnaires. The t- test was applied for comparison of continuous data,and the Pearson correlation analysis was applied for correlation analysis. Results Of all the 415 patients,86( 20. 7%)had NAFLD,consisting of 70 patients( 16. 9%) with mild NAFLD and 16 patients( 3. 8%) with moderate NAFLD. The population with an age of 50- 58 years had the highest prevalence rate( 30. 8%,16 /52). Of all the 86 patients with NAFLD,57( 66. 3%) had obesity,and76( 88. 4%) had abdominal obesity. The employees with moderate NAFLD had a significantly higher alanine aminotransferase( ALT) level,a significantly higher aspartate aminotransferase( AST) level,a significantly larger abdominal circumference,and a significantly higher body mass index( BMI) than those with mild NAFLD( t =- 4. 140,- 3. 512,- 4. 405,and- 5. 051,respectively,all P < 0. 05). In the employees with NAFLD,BMI and abdominal circumference were correlated with AST level( r = 0. 283 and 0. 271,both P < 0. 05) and ALT level( r = 0. 325 and 0. 316,both P < 0. 05). Most employees in this enterprise had a bad eating habit,a sedentary lifestyle,and a lack of physical exercise. Conclusion This enterprise has a high prevalence rate of NAFLD. BMI and abdominal circumference of patients with NAFLD have certain clinical values in predicting the degree of fat deposition in the liver,and are correlated with AST and ALT levels.
[1]NASCIMBENI F,PAIS R,BELLENTANI S,et al.From NAFLD in clinical practice to answers from guidelines[J].J Hepatol,2013,59(4):859-871.
|
[2]WU T,WU S,OUYANG G.Periostin:a new extracellular regulator of obesity-induced hepatosteatosis[J].Cell Metab,2014,20(4):562-564.
|
[3]HONG HC,HWANG SY,CHOI HY,et al.Relationship between sarcopenia and nonalcoholic fatty liver disease:the Korean Sarcopenic Obesity Study[J].Hepatology,2014,59(5):1772-1778.
|
[4]Group of Fatty Liver and Alcoholic Liver Diseases,Society of Hepatology,Chinese Medical Association.Guidelines for management of nonalcoholic fatty liver disease[J].J Clin Hepatol,2010,26(2):120-124.(in Chinese)中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志,2010,26(2):120-124.
|
[5]WEISELL RC.Body mass index as an indicator of obesity.Asia Pacific journal of clinical nutrition[J].Asia Pac J Clin Nutr,2002,11(Suppl 8):s681-s684.
|
[6] SHEN HC,ZHAO ZH,HU YC,et al.Relationship between obesity,metabolic syndrome,and nonalcoholic fatty liver disease in the elderly agricultural and fishing population of Taiwan[J].Clin Interv Aging,2014,9:501-508.
|
[7]BYRNE CD,TARGHER G.Ectopic fat,insulin resistance,and nonalcoholic fatty liver disease:implications for cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2014,34(6):1155-1161.
|
[8]PETTA S,ARGANO C,COLOMBA D,et al.Epicardial fat,cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease:association with the severity of liver disease[J].J Hepatol,2015,62(4):928-933.
|
[9]MUSSO G,GAMBINO R,TABIBIAN JH,et al.Association of non-alcoholic fatty liver disease with chronic kidney disease:a systematic review and Meta-analysis[J].PLo S Med,2014,11(7):e1001680.
|
[10]TARGHER G,BYRNE CD.Clinical Review:nonalcoholic fatty liver disease:a novel cardiometabolic risk factor for type 2 diabetes and its complications[J].J Clin Endocrinol Metab,2013,98(2):483-495.
|
[11]RINELLA ME.Nonalcoholic fatty liver disease:a systematic review[J].JAMA,2015,313(22):2263-2273.
|
[12]XU C,WAN X,XU L,et al.Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia:one stone hits two birds[J].J Hepatol,2015,62(6):1412-1419.
|
[13]WANG FS,FAN JG,ZHANG Z,et al.The global burden of liver disease:the major impact of China[J].Hepatology,2014,60(6):2099-2108.
|
[14]WONG VW,CHU WC,WONG GL,et al.Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese:a population study using proton-magnetic resonance spectroscopy and transient elastography[J].Gut,2012,61(3):409-415.
|
[15]CHALASANI N,YOUNOSSI Z,LAVINE JE,et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology[J].Gastroenterology,2012,142(7):1592-1609.
|
[16]HUBEL JM,SCHMIDT SA,MASON RA,et al.Influence of plasma cortisol and other laboratory parameters on nonalcoholic fatty liver disease[J].Horm Metab Res,2015,47(7):479-484.
|
[17] LEE YH,BANG H,PARK YM,et al.Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease:development,validation and comparison with other scores[J].PLo S One,2014,9(9):e107584.
|
[18]GONZALEZ-CAMPOY JM,GARVEY WT,HARRELL RM.AACE response to a candid discussion of obesity[J].Am J Med,2015,128(10):e57.
|
[19]LIU Z,HU Y,YANG X,et al.Combinative analysis of factors influence serum alanine aminotransferase activity in adult male population from southern China[J].Clin Biochem,2012,45(18):1683-1688.
|
[20]OH S,SHIDA T,YAMAGISHI K,et al.Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease:a retrospective study[J].Hepatology,2015,61(4):1205-1215.
|
[21]GE JB,XU YJ.Internal medicine[M].8th ed.Beijing:People’s Medical Publishing House,2013:769-774.(in Chinese)葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:769-774.
|
[22]CHEN WX,HUANG Y,QIN SM,et al.Jiangzhi Decoction for nonalcoholic fatty liver disease[J].Jilin J Tradit Chin Med,2014,34(11):1127-1129.(in Chinese)陈伟霞,黄芸,秦书敏,等.降脂合剂治疗非酒精性脂肪肝[J].吉林中医药,2014,34(11):1127-1129.
|